Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M. Foon KA, et al. Among authors: boyiadzis m. Blood. 2012 Mar 29;119(13):3184-5. doi: 10.1182/blood-2012-01-408047. Blood. 2012. PMID: 22461474 Free article. No abstract available.
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A. Foon KA, et al. Among authors: boyiadzis m. J Clin Oncol. 2009 Feb 1;27(4):498-503. doi: 10.1200/JCO.2008.17.2619. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075274
Approved monoclonal antibodies for cancer therapy.
Boyiadzis M, Foon KA. Boyiadzis M, et al. Expert Opin Biol Ther. 2008 Aug;8(8):1151-8. doi: 10.1517/14712598.8.8.1151. Expert Opin Biol Ther. 2008. PMID: 18613766 Review.
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Lentzsch S, et al. Among authors: boyiadzis m. Blood. 2012 May 17;119(20):4608-13. doi: 10.1182/blood-2011-12-395715. Epub 2012 Mar 26. Blood. 2012. PMID: 22451423 Free PMC article. Clinical Trial.
Natural killer cells: from bench to cancer therapy.
Boyiadzis M, Foon KA. Boyiadzis M, et al. Expert Opin Biol Ther. 2006 Oct;6(10):967-70. doi: 10.1517/14712598.6.10.967. Expert Opin Biol Ther. 2006. PMID: 16989578 Review.
98 results